Lilly to acquire ImClone; Bristol abandons buyout bid

10/6/2008 | Bloomberg · Reuters

Eli Lilly and Co. confirmed that it will pay $6.5 billion to take over ImClone Systems, maker of cancer treatment Erbitux. The move allows Lilly to expand its pipeline as it prepares to counter generic competition for Zyprexa, a top-selling schizophrenia drug. Bristol-Myers Squibb said it expects to get about $1 billion by selling its shares in ImClone, but it will continue to co-market Erbitux in the U.S.

View Full Article in:

Bloomberg · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA